However, contrary to our findings, Kendall et al.'s meta-analysis on incretin-based therapies in the Asian population with T2D concluded that of all GLP-1 receptor agonist analogs, exenatide was the only drug that resulted in significant weight loss in an Asian population. The gene discussed is GCG; the disease is type 2 diabetes mellitus.